Roche: stopping Xenical from slimming down

Published By Datamonitor

Roche: hoping for a better 2002

Much of the fall was due to the troubled vitamin and fine chemicals division, which Roche may well sell this year. However, the pharmaceutical division also had problems. Things may be better 2002, within the cardiovascular sphere at least. If weight loss drug Xenical is approved in type 2 diabetics, the market potential will be considerable.

Published By Datamonitor

Roche: HIV announcement to dispel pipeline fears

Published By Datamonitor

Roche/Schering-Plough: interferon therapy shows potential

According to French research, certain types of B cell lymphoma respond to the hepatitis C immunotherapy, interferon alfa. While this isn't the first time HCV has been linked with lymphoma, the results should still persuade makers of interferon alfa drugs, such as Roche and Schering-Plough to investigate usage in this indication.

Published By Datamonitor

Roche/Genentech: Herceptin poised for an expanded role

Scientists have found that HER-2 is a key contributor to the development of pre-invasive breast cancer. Roche/Genentech's Herceptin, currently used to treat advanced breast cancer, can target HER-2. However, the detection of elevated HER-2 is not routine among most physicians. Despite this, Herceptin is well positioned to build its usage in early-stage and pre-cancerous populations.

Published By Datamonitor

Roche/DeCODE: a long-term challenge for obesity and anxiety

Published By Datamonitor

Pharmaceutical Licensing Weekly Review: August 19 - 23, 2002

Last week's licensing news featured three of the world's biggest pharmaceutical companies: first GlaxoSmithKline joined Pfizer in an alliance with Argonaut, then Pharmacia joined forces with BattellePharma. Johns Hopkins University also had a busy week beating out deals with Crucell and Correlogic Systems. Finally Amgen and Praecis agreed to terminate their failed relationship.

Published By Datamonitor

Personal care: convenience is second most important innovation driver, behind beauty

Published By Datamonitor

Personal care products: natural ingredients are driving innovation

Published By Datamonitor

Oxford GlycoSciences: Vevesca paves the way

Published By Datamonitor